Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s What You Need to Know About IntelliPharmaCeutics Intl Inc (USA) (IPCI)

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) is a tiny Canadian biotech with no approved products and a market capitalization of a little over $40 million at last count. It generates virtually no revenues, and its entire cash holding derives from a $5.2 million public offering that closed at the beginning of last month. It’s down close to 20% on its 2016 open, and 56% on last year’s highs. That’s the bad. The good is this: it’s got an extended release oxycodone candidate that doesn’t need a phase III data to qualify for an NDA submission, and that submission is expected next month. If the FDA approves the application, it’s lead candidate, Rexista XR, will target a $2.3 billion extended release oxycodone market, in which the two currently approved options lack one or more of the features Rexista XR exhibits.

In short, it’s an extremely risky allocation, but with a very large potential upside if the stars align in the company’s favor. IntelliPharmaCeutics just offered an update as to a couple of key loose ends in advance of the August filing. Here’s what’s important, and what to watch going forward.

The update covered two points, with one relating to the drug and the other relating to the application. We’ll address the former first.

FDA drug testing

The drug, Rexista, is based on a system called the Novel Point Of Divergence Drug Delivery System (NPODDS). It’s pretty much exactly what it sounds like – on administration a drug has an immediate (but limited) loading dose that acts as a initial response to whatever pain it’s targeting. Beyond that, a second load doses, but this one is a steady, sustained release dose. It’s also got a host of abuse deterrent features. It coagulates if crushed and mixed with water, so it can’t be injected. It’s really tough to vaporize without what’s called pyrolization, which is essentially the decomposing of the active oxycodone ingredient. If you grind it with a goal of snorting or chewing it, it releases a blue dye that stains the entry point. It has a low reactive response to alcohol, which helps to avoid dose dumping. There are a few more, but these are the key points. It’s both quick and extended release, and it is really tough to abuse.

The most interesting point is this, however. The drug’s pathway to approval is based on a system called 505(B)(2). There are essentially three ways a drug can go from discovery to market – 505(b)(1) NDA, 505(b)(2) NDA and 505(j) ANDA. The latter is for generic drugs. The first is the standard process (discovery, sponsor conducts phase I, II and III, etc. Rexista’s pathway, 505(b)(2) NDA, is applicable when the drug in question is based on a combination of drugs already deemed safe and effective, and it can rely on data already produced to form the basis of an NDA. The update we are looking at covered the completion of what is essentially the only extensive data IntelliPharmaCeutics has had to produce itself, proof of concept aside, and it relates to the impact of food on Rexista’s efficacy. The result, there is none, which gives it an advantage over Xtampza, one of the drugs that Rexista will be competing against.

The second point relates to a waiver of the costs associated with the NDA submission. These are called user fees, and came about with the introduction of the PDUFA back in 1992. The cost for a submission like the one IntelliPharmaCeutics is putting forward is $1,187,100 for 2016, up a little bit on last year’s fee of $1,167,600. There are four different waiver categories – public health, barrier to innovation, financial considerations (these are mainly reductions rather than waivers) and small business. Given its size and revenues, IntelliPharmaCeutics qualifies for the last one, small business, meaning the FDA will waive its NDA submission fee.

So what are we looking for going forward?

The submission of the FDA should be the next major catalyst, and while there’s no guarantee that the company will hit its target, IntelliPharmaCeutics expects a submission during August this year. Beyond that, PDUFA should come relatively quickly, given the nature of the application. Again, to reiterate, this is a really risky allocation. Financially the company is at the very low end of what’s acceptable. From an opportunity perspective, however, it’s well worth a look as a possible small speculative play.

Follow Intellipharmaceutics Intl Inc (NASDAQ:IPCI)
Trade (NASDAQ:IPCI) Now!

Note: This article is written by Jennifer Aldershot and originally published at Market Exclusive.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!